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Abstract
Obesity is associated closely with the metabolic syndrome (MS). It is well
known that obesity-induced chronic inflammation plays a fundamental role in
the pathogenesis of MS. White adipose tissue (AT) is the primary site for the
initiation and exacerbation of obesity-associated inflammation. Exploring the
mechanisms of white AT inflammation and resetting the immunological balance
in white AT could be crucial for the management of MS. Several prominent
molecular mechanisms have been proposed to mediate inflammation in white
AT, including hypoxia, endoplasmic reticulum stress, lipotoxicity, and metabolic
endotoxemia. Recently, a growing body of evidence supports the role of miRNAs
as a new important inflammatory mediator by regulating both the adaptive and
innate immunity. This review will focus on the implication of miRNAs in white AT
inflammation in obesity, and will also highlight the potential of miRNAs as targets
for therapeutic intervention in MS as well as the challenges lying i...
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Obesity is associated closely with the metabolic syndrome (MS). It is well known that obesity-induced chronic inflammation plays
a fundamental role in the pathogenesis of MS. White adipose tissue (AT) is the primary site for the initiation and exacerbation of
obesity-associated inflammation. Exploring the mechanisms of white AT inflammation and resetting the immunological balance
in white AT could be crucial for the management of MS. Several prominent molecular mechanisms have been proposed to mediate
inflammation in white AT, including hypoxia, endoplasmic reticulum stress, lipotoxicity, and metabolic endotoxemia. Recently, a
growing body of evidence supports the role of miRNAs as a new important inflammatory mediator by regulating both the adaptive
and innate immunity. This review will focus on the implication of miRNAs in white AT inflammation in obesity, and will also
highlight the potential of miRNAs as targets for therapeutic intervention in MS as well as the challenges lying in miRNA-targeting
therapeutics.
1. Introduction
The incidence of obesity defined as body mass index (BMI) ≥
30 kg/m2 has increased drastically worldwide during recent
decades. Obesity is associated with a cluster of metabolic
disorders, including increased risk of insulin resistance,
type 2 diabetes (T2DM), hypertension, dyslipidemia, and
cardiovascular disease; these disorders and obesity per se
constitute a serious threat, known as the metabolic syndrome
(MS) [1]. It is well known that chronic inflammation is a key
feature of obesity; this obesity-induced inflammation builds
the common soil for the pathogenesis of MS [2]. Therefore,
resetting the immunological balance in obesity is a crucial
approach for the management of MS.
White adipose tissue (AT) has been regarded as the
primary goal of pharmacological intervention since obesity-
induced inflammation is mainly initiated and exacerbated
in this organ [3–5]. Although several prominent molecular
mechanisms have been proposed to trigger inflammation
in white AT, including hypoxia, endoplasmic reticulum
stress, lipotoxicity, and metabolic endotoxemia [5], these
factors cannot fully explain the origin of inflammation.
On the other hand, current anti-inflammatory strategies
are not sufficient enough in the treatment of MS. These
facts suggest that there are lots of unknowns responsible
for AT inflammation in obesity. In recent years, a growing
body of evidence has highlighted the modulating roles
of miRNAs in immune/inflammatory system [6, 7] and
their involvement in the obesity-related metabolic disorders
including T2DM and atherosclerosis [8, 9]. Specific miRNAs
have been implicated in adipogenesis and mature adipocyte
function [10]. As yet, whether thesemiRNAs could be another
mechanism for mediating AT inflammation and whether
these tiny molecules could serve as potent therapeutic anti-
inflammatory targets forMS are still not fully settled.The aim
of the present review is to address these questions.
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2. Obesity, Inflammation,
and Metabolic Syndrome
2.1. Low-Grade Inflammation as a Key Feature of Obesity.
During the past decade, it became clear that inflammation
is a key feature of obesity [2]. The inflammatory response
triggered by obesity involves many components of the clas-
sical inflammatory response to pathogens and includes the
increases in circulating inflammatory cytokines and acute-
phase proteins (e.g., C-reactive protein), recruitment of
leukocytes to inflamed tissues, activation of tissue leuko-
cytes, and generation of reparative tissue responses (e.g.,
fibrosis). However, the nature of obesity-induced inflam-
mation, referred to as “metainflammation” (metabolically
triggered inflammation), is unique compared with other
inflammatory paradigms (e.g., infection and autoimmune
disease) in several key aspects. First, the chronic nature of
obesity produces a low-grade activation of the innate immune
system that affects metabolic homeostasis over time. Second,
childhood obesity may place individuals at risk for lifelong
inflammation, since inflammatory markers are elevated in
obese children as young as 3 years old. Third, this chronic
inflammation is composed of recurrent acute episodes of
nutrition-related immune activation induced by nutrient
availability (fasting or high-fat meals). This fluctuation may
be associatedwith the induction of pro- or anti-inflammatory
mediators. Finally, obesity-induced chronic inflammation is
unique by its multiorgan involvement [11].
2.2. Obesity-Induced Inflammation Linking Obesity to Meta-
bolic Syndrome. The metabolic syndrome (MS) refers to the
clustering of cardiovascular risk factors that include central
obesity, hyperglycemia, dyslipidemia, and hypertension. The
ultimate importance of this cluster is to identify individuals at
high risk of both T2DM and cardiovascular disease. Growing
evidence implicates obesity-induced inflammation as an
important mechanism linking obesity to the MS in metabol-
ically active organs. Assessment of gene expression networks
in obese AT has identified a robust pattern of overexpressed
inflammatory genes associated with metabolic disease [12,
13]. Multiple inflammatory mediators abnormally secreted
by AT and the crosstalk between immune and metabolic
cells can impair insulin signaling and induce oxidative
stress and endothelial dysfunction, leading to systemic
insulin resistance and cardiovascular disease [5]. Deregulated
macrophage-myocyte and macrophage-hepatocyte signaling
can impair insulin sensitivity as well [14, 15]. Hypothalamic
inflammation, which is induced very rapidly by a high-fat
diet [16]may provoke hyperphagia and has been documented
to impair insulin release from 𝛽 cells, peripheral insulin
action, and potentiate hypertension [17–19]. Thus, chronic
excess of nutrients, such as lipids and glucose may simultane-
ously trigger inflammatory responses, which further disrupt
metabolic function, enhancing stress, and inflammation.
Such a vicious cycle is identified as a mechanism leading
to further metabolic deterioration. Therefore, breaking this
vicious circle by resetting the immunological balance in
obesity is a crucial approach for the management of MS.
3. The Fundamental Role of White Adipose
Tissue in Obesity-Induced Inflammation
Obesity is characterized by excessive expansion of white
adipose tissue (AT), which has been thought to be the
primary site for the initiation of obesity-associated inflam-
mation. Although AT’s principal function deals with energy
storage, it serves as an active secretory organ as well. A
number of bioactive peptides or proteins, collectively named
“adipokines,” are produced and secreted by fat and/or nonfat
cells of white AT. They act in an autocrine/paracrine manner
to regulate local AT function and also act in an endocrine
manner to influence the functions of distant tissues such as
liver, skeletal muscle, and cardiovascular and central nervous
systems [5, 20].
In obesity, white AT is remodeled dynamically by adi-
pocyte hypertrophy (increased size), hyperplasia (increased
number), immune cell infiltration, endothelial cell over-
activation, and extracellular matrix overproduction [21–
24]. This remodeling may trigger metabolic and hypoxic
stress, resulting in activation of multiple inflammatory
signaling pathways, ultimately leading to dysregulation of
numerous adipokines including proinflammatory cytokines,
chemokines, growth factors, acute-phase proteins, and
complement-like factors. Virtually, all known adipokines are
dysregulated in obesity via multiple mechanisms. Such a
deregulation is the main feature of AT low-grade inflamma-
tion and contributes to the pathogenesis of MS [5].
4. Molecular Mechanisms Mediating White
Adipose Tissue Inflammation
Several prominent mechanisms have been highlighted that
coordinately mediate white AT inflammation.
Hypoxia. In obesity, the growing AT is submitted to hypoxia
induced by hypoperfusion at the earliest stages of expansion.
Observations have proved that AT is poorly oxygenated in
the obese state in humans and rodents due to a reduction
in adipose tissue blood flow [25, 26]. This hypoxia could be
a determinant mediator of obesity-induced inflammation in
ATby activatingmultiple signaling pathways such asHypoxia
Inducible Factor-1𝛼 (HIF-1𝛼) and Nuclear Factor kappa B
(NF-𝜅B) in adipocytes andmacrophages, thereby altering the
expression of many proinflammatory adipokines [27–29]. In
addition, some studies reported that hypoxia also induces
AT inflammatory responses indirectly by causing adipocyte
death (e.g., apoptosis and necrosis) and lipolysis [30–32].
Endoplasmic Reticulum Stress. The endoplasmic reticulum
(ER) is responsible for much of a cell’s protein synthesis and
folding, but it has also a role in sensing cellular stress [33].
Obesity results in conditions that increase the demand on the
ER, such as hypoxia and excess of cytokines, lipids, or glucose.
Subsequently, the ER stress induces a complex response
known as the unfolded protein response (UPR), which alters
a cell’s transcriptional and translational programs to cope
with these stressful conditions and resolve the protein-folding
defect [33]. ER stress and the UPR lead to obesity-induced
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inflammation andmetabolic abnormalities by several distinct
mechanisms, including the activation of JNK-AP1 (Jun N-
terminal Kinase-Activator Protein 1) and IKK (I𝜅B kinase)-
NF𝜅B pathways, the induction of the acute-phase response,
and the production of reactive oxygen species (ROS) [34, 35].
Lipotoxicity. Obesity is characterized by a positive energy
balance, and the classical response to this nutrient oversupply
is AT hypertrophy. However, the capacity for lipid storage in
hypertrophied subcutaneous AT is limited. This limited stor-
age capacity, coupled with the overstimulation of hormone-
sensitive lipase, leads to massive increase in free fatty acid
(FFA) release and accumulation ectopically. FFAs are potent
ligands that activate toll-like receptor (TLR) signaling [36].
TLRs are a family of pattern-recognition receptors that play
a critical role in the innate immune system by activating
proinflammatory signaling pathways in response tomicrobial
pathogens. AT expresses a broad spectrum of TLRs [37–
39]. TLR expression in AT is inducible by inflammatory
stimulation and linked to downstream activation of NF-𝜅B or
JNK and subsequent release of proinflammatory adipokines
[37, 38, 40]. TLR4-deficient mice and C3H/HeJ mice (which
have a loss-of-function mutation in TLR4) are partially pro-
tected from fat-induced inflammation and insulin resistance
in their visceral AT [41, 42]. FFAs also increase the infiltration
and activation of macrophages, especially the CD11c+ subset,
thereby exacerbating their proinflammatory activity [43].
Metabolic Endotoxemia. High-fat diet given to mice chroni-
cally increased plasma Lipopolysaccharide (LPS) concentra-
tion two to three times; a threshold that has been defined
as metabolic endotoxemia [44]. Obese subjects with type
2 diabetes have 76% higher circulating LPS than healthy
controls [39] and this high level of LPS decreased significantly
after surgical weight loss [45]. Elevated plasma LPS levels
result from increased absorption of LPS across the intestinal
barrier triggered by high-fat diet. Recently, three underlying
mechanisms have been proposed, including the changes in
gutmicrobiota environment [44], the increased availability of
chylomicrons [46], and the permeability of the gut epithelium
[47–49]. In murine adipocytes, LPS initiates inflammation
via TLR4 and induces the secretion of proinflammatory
cytokines via downstream activation of NF-𝜅B or mitogen-
activated protein kinases (MAPK) signaling pathways [50].
In human adipocytes, stimulation by LPS increases release of
Tumor Necrosis Factor-alpha (TNF-𝛼), Interleukin-6 (IL-6),
andMonocyte Chemoattractant Protein-1 (MCP-1) byNF-𝜅B
activation andupregulates TLR2 expression.Newly expressed
TLR2 further amplifies proinflammatory signals in AT [39].
5. microRNAs as a New Mechanism Mediating
White Adipose Tissue Inflammation
microRNAs (miRNAs) are endogenous ∼22 nt RNAs that can
bind to the 3󸀠-untranslated region (3󸀠-UTR) of target mRNAs
to repress mRNA expression at the posttranscriptional level.
As a group, miRNAs may directly regulate expression of
over 30% of human and mouse genes and more than 60%
of human protein-coding genes have been under selec-
tive pressure to maintain pairing to miRNAs [51]. Specific
miRNAs have been implicated in adipocyte differentiation
and mature adipocyte function, including lipolysis, glucose-
uptake, and insulin sensitivity [8, 10]. On the other hand,
miRNAs have been defined as important immunomodulators
by regulating the differentiation, induction, and function
of immune cells and the expression of multiple cytokines
in the immune system. These findings could shed light
on the possible links between miRNAs and adipose tissue
immunity/inflammation.
5.1. Role of microRNAs in Inflammation
Role of microRNAs in Adaptive Immunity. Studies conducted
by some groups have demonstrated that miRNA regulation
is indispensable for stable immune process. miRNAs appear
to have a key role in the differentiation of B-cells. Ablation
of whole miRNAs by deletion of Argonaute 2 (Ago2) or
Dicer impairs pre-B-cell differentiation and the succeeding
peripheral B-cell generation [52]. Several individual miRNAs
have also been reported to be involved in the B-cell biology.
For example, overexpression of miR-17∼92 clusters enhances
B-cell proliferation and survival [53], while miR-150 pro-
foundly impairs early B-cell differentiation andmature B-cell
responses [54].
miRNAs have been shown to be key regulators of the
T-cell lineage induction pathways. Deletion of Dicer at an
early stage of T-cell development compromised the survival
of T-cell lineage [55]. The best evidence for miRNAs playing
a role in specific developmental stages of T-cell differen-
tiation is from miR-181, which reduces the number of T-
cells in haematopoietic overexpression systems [56] and also
increases the sensitivity of T-cell receptor signaling [57].
In addition, miRNAs also play pivotal roles in the
induction, function, andmaintenance of the regulatory T-cell
(Treg) lineage. miRNAs can enhance thymic and peripheral
induction of Treg cells [55, 58]. Dicer-deficient Treg cells
almost lost their suppressive capacity and anergic profile [58].
Role of microRNAs in Innate Immunity. Several miRNAs
(includingmiR-155, miR-146a, miR-21, andmiR-9) have been
consistently found to be rapidly induced by innate immune
activation (e.g., toll-like receptor), indicating that they may
regulate the innate immune response [59]. Target prediction
analyses indicate that up to a half of innate immune genes
could be under the direct regulation of miRNAs. A study on
613 genes, which regulate immunity utilizing a computational
approach, identified 285 genes as miRNA targets. Major tar-
gets include transcription factors, cofactors, and chromatin
modifiers whereas upstream factors, such as ligands and
receptors (cytokines and chemokines) were, in general, poor
or nontargets [60].
The mechanisms by which miRNAs regulate cytokine
expression include direct regulation by binding to seeding
sites in mRNA 3󸀠-UTR and indirect regulation. Computa-
tional analyses predict thatmost cytokines lackmiRNA target
sites in 3󸀠-UTRs [60]. For example, of the interleukin genes
(IL1-29) studied, 9 had predicted miRNA binding sites. Out
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of 20 interleukin receptor genes examined, only 2 had high
probability miRNA target sites. These findings suggest that
the regulation of cytokine genes by miRNAs occurs often
via indirect mechanism. Recent studies indicate indeed that
miRNAs could indirectly regulate cytokine genes via AU-rich
elements (ARE) located in the mRNA 3󸀠-UTR by targeting
ARE-binding proteins. ARE are the cis-acting structural RNA
motifs that are important determinants of cytokine message
stability. ARE-mediated mRNA degradation is regulated by
a number of trans-acting factors, called the ARE-binding
proteins (which include tristetraprolin (TTP), AU rich bind-
ing factor 1 (AUF1), and members of the Hu protein R
(HUR) family) [61]. These ARE-binding proteins are heavily
predicted targets of miRNAs [62]. Repression of several ARE
components by miRNAsmay alter the levels of inflammatory
cytokines as well as of other immune genes [60, 62].
5.2. Role of microRNAs in White Adipose Tissue Inflammation
Obesity-Induced Inflammation Is Associated with Dysregu-
lated Expression of miRNAs in White Adipose Tissue. Low-
grade inflammation in AT is a key feature of obesity. A
number of miRNAs have been found dysregulated in white
AT during obesity and closely associated with obesity-
related metabolic disorders. A recent study identified 21
miRNAs, which were differentially expressed in epididymal
AT between lean mice fed a standard diet and mice rendered
obese by a high-fat diet [63]. Ortega et al. performed
miRNA array on human subcutaneous AT: 50 of the 799
miRNAs tested (6.2%) significantly differed between obese
(𝑛 = 9) and lean (𝑛 = 6) subjects [64]. Among these 50
miRNAs, 17 were highly correlated with BMI and metabolic
parameters (fasting glucose and/or triglycerides) [64]. These
data are concordant with those obtained in overweight or
obese subjects by Klo¨ting et al. They showed significant
correlations between the expression of selected miRNAs
and both AT morphology and key metabolic parameters,
including visceral fat area, HbA1c, fasting plasma glucose,
and circulating leptin, adiponectin, and IL-6 [65]. Another
two miRNAs (miR-17–5p and miR-132) were significantly
decreased in the omental fat and the circulation of obese
subjects [66]. A very recent study defined a set of eleven
adipocyte-specific miRNAs downregulated in obese subjects
as all of them were concomitantly altered in both the white
AT and the isolated adipocytes [67]. Moreover, inflammation
per se could alter white AT miRNA levels. Xie et al. showed
that TNF-𝛼 treatment of 3T3-L1 adipocytes mimicked the
changes of miRNA expression observed in AT of obese mice
[68]. With obesity and inflammation being so intrinsically
associated, the dysregulated expression ofmiRNAs in inflam-
matory adipocytes highly suggests the particular importance
of miRNAs in obesity-induced inflammation.
Individual miRNAs Regulate White Adipose Tissue Inflamma-
tion. Indeed, a few individual miRNAs have been reported
as playing a crucial role in the inflammatory state of AT
so far (Figure 1). Expression of miR-221 and miR-222 has
been positively correlated to TNF-𝛼 and negatively corre-
lated to ApN expression in white AT of mice [69]. Yet,
the direct effects of both miRNAs on these pro- or anti-
inflammatory adipokines are still unraveled. miR-132, which
was downregulated in human obese omental fat [66], has
been reported to activate NF-𝜅B and the transcription of IL-
8 and MCP-1 in primary human preadipocytes and in in
vitro differentiated adipocytes [70]. Zhuang et al. demon-
strated that miR-223 played a crucial role in modulating
macrophage polarization in a pattern that protects mice
from diet-induced AT inflammation and systemic insulin
resistance. Consequently, miR-223 suppressed the infiltration
of proinflammatory M1 “classically activated” macrophages
by targeting Pknox1 in vitro, while miR-223 deficient mice
fed a high-fat diet exhibited increased AT inflammation
characterized by enhanced proinflammatory activation of
macrophages [71]. The group of Brichard has identified
several miRNAs, which were regulated by adiponectin (a
promising anti-inflammatory adipokine) in white AT in vivo.
The miR883b-5p, which was upregulated by adiponectin and
downregulated in human obesity repressed the LPS-binding
protein (LBP) andTLR4 signaling, acting therefore as amajor
mediator of the anti-inflammatory action of ApN. Moreover,
miR883b-silencing in the de novo AT formed from in vivo
differentiation of preadipocytes also induced LBP production
and tissue inflammation [72]. Very recently, Arner et al.
overexpressed individual miRNAs (which have been defined
downregulated inAT in human obesity) in human adipocytes
differentiated in vitro. They found that a set of nine miRNAs
significantly reduced the secretion of chemokine (C-Cmotif)
ligand 2 (CCL2) which is an initiator of AT inflammation
by attracting the migration of inflammatory cells into the
tissue. Among these miRNAs, only miR-126 was predicted
by in silico analysis and confirmed by luciferase reporter
assay in 3T3-L1 cells to bind directly to the 3󸀠-UTR of CCL2,
whereas miR-193b affected indirectly the CCL2 production
through downregulating the transcription factors (TFs) of
CCL2 (RELB, STAT6, and ETS1) [67]. Thus, miRNAs may
mediate AT inflammation by regulating either the activation
of macrophages or the production of adipokines. The mech-
anism by which miRNAs regulate adipokines in AT seems
via direct and indirectmechanisms.miRNAsmay act directly
on the target inflammatory adipokines or indirectly by first
regulating the intermediate machinery components like the
TFs, which, in turn, control the expression of adipokines.
In addition to the innate immunity, recent studies have
disclosed the importance of the adaptive immunity in AT
inflammation.The subsets of the lymphocyte lineage, includ-
ing CD8+ and CD4+ T-cells, Tregs, Natural killer T-cells
(NKT), and B-cells have been revealed to infiltrate into AT
which may orchestrate AT inflammation. Lymphocyte infil-
tration into AT could even precede macrophage infiltration
[73, 74]. Yet, the mechanisms underlying the infiltration of
lymphocytes into AT remain largely unknown (Figure 1).
Whether miRNAs could play roles in modulating the infil-
tration or activation of the lymphocytes in AT may arouse
research interest and requires to be investigated in the future.
miRNAsMediate Intercellular Communication.More recently,
adipocytes have been reported to secrete miRNAs in the
form of adipocyte-derived microvesicles (ADMs), which
Journal of Immunology Research 5
Lymphocyte
miRNAs
Pknox1
M1
miRNA
Microvesicle
ApN
miR-884b-5p
LBP
LBP LPS
Adipocyte
miR-132
Macrophage
miR-126
CCL2
miR-193b
?
miR-223
NF-𝜅B
IL-8, and MCP-1
RELB, STAT6, and ETS1
Figure 1: Scheme for the miRNA-mediated mechanisms in regulating white adipose tissue inflammation. The miR-132 activates NF-𝜅B and
the transcription of downstream adipokines IL-8 and MCP-1. The miR-223 played a crucial role in modulating macrophage polarization,
which suppresses the infiltration of proinflammatory M1 “classically activated” macrophages by targeting Pknox1. The miR883b-5p, which is
upregulated by ApN represses the expression and secretion of LBP, a LPS facilitator.ThemiR-126 reduces the production of CCL2 by targeting
directly the 3󸀠-UTR of CCL2, while miR-193b inhibited indirectly the CCL2 production through downregulating the transcription factors of
CCL2 (RELB, STAT6, and ETS1). The microvesicles released by adipocytes may either go into circulation or transfer into the neighboring
adipocytes ormacrophages, probably acting as inflammatory communicators between adipocytes, macrophages, and distant cells.The arrows
indicate stimulation or activation; blunted arrows indicate inhibition. ApN, adiponectin; LBP, LPS-binding protein; LPS, lipopolysaccharide;
CCL2, chemokine (C-C motif) ligand 2, adapted from [5].
may regulate the function of distant or neighboring cells.
One study found that microvesicles released from cultured
3T3-L1 adipocytes harbored 143 miRNAs, most of them
being adipocyte-specific and reflecting the abundance of
their expression levels in the donor cells. Interestingly,
the miRNAs-containing microvesicles were transported into
cultured macrophages which were incubated with ADMs
containing-medium for 24 h; they were also present in rat
serum in vivo [75]. Yet, whether the miRNAs inside the
vesicles were functional in their new location remains to
be determined. Furthermore, another group discovered that
miRNAs-microvesicle complexes derived from the larger
primary rat adipocytes were transferred into and expressed in
the smaller adipocytes and were involved in the transcription
of multiple genes for lipid synthesis and cell growth [76].
Thus, miRNAs could also be important mediators of cellular
crosstalk. Since macrophages and hypertrophied adipocytes
are the main sources of AT inflammation, the miRNA-
mediated interactions (adipocytes-macrophages and larger
adipocytes-smaller adipocytes)may be novelmechanisms for
miRNAs contributing to AT inflammation (Figure 1).
6. Therapeutic Potential of microRNAs in
Metabolic Syndrome
The facts that miRNAs are largely dysregulated in obe-
sity and that specific miRNAs regulate obesity-associated
inflammation suggests the potential of these molecules as
targets for therapeutic intervention in obesity and obesity-
related metabolic disorders.
6.1. microRNAs as Diagnostic Tools. Recent studies have
demonstrated that miRNAs can be secreted into the circula-
tion. Chen et al. screened serummiRNAs of healthy Chinese
subjects and found over 100 and 91 serum miRNAs in male
and female subjects, respectively. Yet, how these miRNAs
make their way into the circulation is still mysterious [77].
New studies have revealed that circulatingmiRNAs can reside
in microvesicles (exosomes, microparticles, and apoptotic
bodies) and in protein/lipoprotein complexes (high density
lipoprotein (HDL) and Argonaute 2); these formations make
the circulating miRNAs protected and resistant to RNase
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activity and degradation. Therefore, the levels of miRNAs
in serum are remarkable, stable, reproducible, and tissue-
specific among individuals. This raises the potential of miR-
NAs as novel biomarkers formany disorders.Multiple reports
have noted the potential use of blood miRNAs as biomarkers
for the obesity, cardiovascular diseases, atherosclerosis, and
T2DM. Heneghan et al. showed that circulating levels of
miR-17-5p and miR-132 were significantly decreased in obese
individuals compared to nonobese individuals and reflected
miRNA expression in omental fat. The miRNA expression
in blood and omental fat from obese patients correlated
significantly with BMI, fasting blood glucose, and glycated
hemoglobin [66]. Cardiac specific miR-1, miR-208, and miR-
499 were induced consistently in blood of patients with
myocardial infarction and strongly correlated to markers of
cardiac damage including troponin T and creatine kinase-
MB (CK-MB) activity [78–81]. CirculatingmiRNAs have also
been proposed as highly sensitive biomarkers for T2DM. In
the Bruneck cohort of 822 subjects, decreased serum levels
of miR-126 in T2DM emerged as a significant predictor
of T2DM and correlated negatively with increasing glucose
intolerance [82].
6.2. microRNAs as Therapeutic Tools. “Silencing” of key
miRNA and “replacement” of certain tissue-specific miRNA
whose expression is known to be decreased are potential
therapeutic interventions.
Techniques. Several techniques have been set up to use the
therapeutic potential of miRNAs. miRNAs can be deacti-
vated and silenced by anti-miRNA oligonucleotides (AMOs),
“miRNA sponges,” and “miRNA masking” [83]. AMOs
are synthetic antisense oligonucleotides that competitively
inhibit the interaction between miRNAs and their mRNA
targets. The most widely employed types of AMOs are 2󸀠-
O-methyl AMO, 2󸀠-O-methoxyethyl AMOs, and Locked
Nucleic Acids (LNAs) [84]. Given that miRNAs have been
observed to function often in clusters in pathological pro-
cesses, the “miRNA sponges” have been developed to knock-
down multiple miRNAs. This technique requires a vector
encoding large quantities of transcripts (anti-miRNAs)which
display numerous and tandem binding sites for a cluster of
miRNAs of interest. The “miRNA masking” is an alternative
miRNA-knockdown strategy to the AMO approach, with
the advantage of targeting miRNAs in a gene-specific man-
ner. Unlike AMO, which binds to the endogenous miRNA
directly, a miRNA mask binds to the miRNA’s binding site
located in the 3󸀠-UTR of its target mRNA, thereby avoiding
off-target effects [83].
Conversely, with regard to those miRNAs with decreased
expression in disease, the fundamental principle strategy is
to restore their expression. This can be achieved through
miRNA mimicry or plasmid/viral vector-encoded miRNA
replacement. miRNA mimics are small chemically altered
double-stranded RNA molecules that imitate endogenous
miRNAs [83]. Plasmid/viral vectors encoding miRNAs are
encouraging strategies to replace miRNA in vivo, with good
transduction efficiency and minimal toxicity [85, 86].
microRNAs and Therapeutics. Since the obesity-induced
inflammation is considered to build the common soil for
the pathogenesis of MS, some potential anti-inflammatory
therapies have been investigated. Several drugs in current
clinical practice show the anti-inflammatory properties: the
peroxisome proliferator-activated receptor (PPAR) family
and nonacetylated salicylates. Other strategies have been
explored by targeting the cytokines and chemokines or their
receptors (e.g., the anti-TNF or anti-CCR2 (chemokine (C–C
motif) receptor 2) therapies) [2]. Although there have been
some encouraging results, it is likely that the benefits of these
approaches are limited [87, 88]. Therefore, the development
of miRNA-based therapeutics has raised interest in this field.
To date, the greatest efforts have been made in exploring
the potential application of miRNAs therapeutics in cancer
and liver disorders. Gain or loss of function of individual
miRNAs have been reported in almost every solid and
hematological cancer, with therapeutic suppressing effect
in tumor cell proliferation, progression of tumors, and the
metastatic process [83]. The liver specific miR-122 has been
proved to regulate cholesterol biosynthesis and hepatitis C
virus replication. Silencing of miR-122 by intraperitoneal
administration of high affinity LNAanti-miR-122 has resulted
in dose-dependent lowering of plasma cholesterol in mice
and nonhuman primates (monkeys).This was achieved with-
out significant adverse reactions or hepatic toxicity [89, 90].
Likewise, induction or reduction of miRNA expression
that is known to be under/upper-expressed and involved in
AT inflammation using viral or liposomal delivery of tissue-
specific miRNAs to affected AT could potentially result in
restoration of immune balance to the AT. Yet, the application
of miRNAs therapeutics in AT in vivo is poorly investigated
because fat cells are insusceptible to selective transfer of
exogenous nucleotide due to the containing lipid droplets
of adipocytes. Encouragingly, the discovery that miRNAs
could be secreted by adipocytes and accepted by neighboring
adipocytes or macrophages in the form of adipocyte-derived
microvesicles [75, 76] raises the hope that it could be possible
to import the targeting miRNAs into AT in vivo by the
manner of microvesicles. This manner could construct the
microvesicles containing specific miRNAs and inject the
constructed microvesicles into white AT.
6.3. Potential Challenges in microRNA-Based Therapy.
Although significant advances have been made in miRNA-
based therapy, various challenges remain to be overcome
before clinical use. First, one individual miRNA may
have multiple potential targets, which may coordinate or
antagonize each other’s functions. In addition, miRNA-
target interactions depend not only on the sequence of
the target site but also on the cellular context, in which the
interactions occur.This complexity explains the difficulties in
predicting the spectrum of side effects and toxicity profiles,
which may be associated with miRNA-based therapeutics.
Second, replacement of miRNA may potentially lead to
oversaturation of endogenous miRNAs pathway. High levels
of exogenous miRNA can compete with the endogenous
miRNA biogenesis processing, leading to cell toxicity
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[91, 92]. Another critical issue is the site-specific, safe,
effective, and repeated delivery of miRNA in vivo. The
systemic intravenous delivery of viral or liposomal-mediated
miRNA oligonucleotides have been well achieved in cancer
and liver disease. However, targeting certain miRNAs in
other specific tissues is poorly achieved due to the invasive
nature of access for repeat delivery and lack of cell-specific
up-take. Restoration of tissue-specific miRNA expression
could be a more rational approach for managing local
abnormalities with more efficiency and precision and with
less systemic side effects [83, 92].
7. Conclusion
Evidence has provided that miRNAs are largely dysregulated
in white AT in human obesity; specific miRNAs regulate the
polarization ofmacrophages and the expression and secretion
of adipokines in white AT; a subset ofmiRNAs could be pack-
aged into adipocyte-derived microvesicles and delivered into
blood or neighboring cells,mediating intercellular communi-
cation. Several reports strongly support the roles of miRNAs
as important mediators in AT inflammation. Furthermore,
with the recent discovery that miRNAs are secreted into
circulation in a stable manner and correlated closely with
crucial metabolic parameters, the plasma miRNA profiles
could therefore be used as attractive biomarkers for the
MS. Finally, the establishment of miRNAs-based techniques
allows exploring further fascinating roles of miRNAs and
their applications in the management of MS. Despite huge
challenges lying in miRNA-targeting therapeutics, especially
in developing safe and effective delivery of targeting miRNAs
in specific tissues in vivo, the development of miRNA-based
therapeutics for MS is warranted because of the severe
problem that metabolic disease poses to society.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
This work was supported by grants from the National Key
Clinical Department Construction Project.
References
[1] Y.-H. Tseng, A. M. Cypess, and C. R. Kahn, “Cellular bioen-
ergetics as a target for obesity therapy,” Nature Reviews Drug
Discovery, vol. 9, no. 6, pp. 465–482, 2010.
[2] G. S. Hotamisligil, “Inflammation and metabolic disorders,”
Nature, vol. 444, no. 7121, pp. 860–867, 2006.
[3] K. L. Spalding, E. Arner, P. O. Westermark et al., “Dynamics of
fat cell turnover in humans,”Nature, vol. 453, no. 7196, pp. 783–
787, 2008.
[4] P. Jiao andH. Xu, “Adipose inflammation: cause or consequence
of obesity-related insulin resistance,” Diabetes, Metabolic Syn-
drome and Obesity, vol. 1, pp. 25–31, 2008.
[5] E.Maury and S.M. Brichard, “Adipokine dysregulation, adipose
tissue inflammation and metabolic syndrome,” Molecular and
Cellular Endocrinology, vol. 314, no. 1, pp. 1–16, 2010.
[6] L.-F. Lu and A. Liston, “MicroRNA in the immune system,
microRNA as an immune system,” Immunology, vol. 127, no. 3,
pp. 291–298, 2009.
[7] D. Sayed and M. Abdellatif, “Micrornas in development and
disease,” Physiological Reviews, vol. 91, no. 3, pp. 827–887, 2011.
[8] H. M. Heneghan, N. Miller, and M. J. Kerin, “Role of microR-
NAs in obesity and the metabolic syndrome,” Obesity Reviews,
vol. 11, no. 5, pp. 354–361, 2010.
[9] M. Hulsmans, D. De Keyzer, and P. Holvoet, “MicroRNAs
regulating oxidative stress and inflammation in relation to
obesity and atherosclerosis,” The FASEB Journal, vol. 25, no. 8,
pp. 2515–2527, 2011.
[10] R. Alexander, H. Lodish, and L. Sun, “MicroRNAs in adipoge-
nesis and as therapeutic targets for obesity,” Expert Opinion on
Therapeutic Targets, vol. 15, no. 5, pp. 623–636, 2011.
[11] C. N. Lumeng and A. R. Saltiel, “Inflammatory links between
obesity andmetabolic disease,”The Journal of Clinical Investiga-
tion, vol. 121, no. 6, pp. 2111–2117, 2011.
[12] Y. Chen, J. Zhu, P. Y. Lum et al., “Variations in DNA elucidate
molecular networks that cause disease,” Nature, vol. 452, no.
7186, pp. 429–435, 2008.
[13] V. Emilsson, G. Thorleifsson, B. Zhang et al., “Genetics of gene
expression and its effect on disease,” Nature, vol. 452, no. 7186,
pp. 423–428, 2008.
[14] V. Varma, A. Yao-Borengasser, N. Rasouli et al., “Muscle inflam-
matory response and insulin resistance: synergistic interaction
between macrophages and fatty acids leads to impaired insulin
action,”The American Journal of Physiology: Endocrinology and
Metabolism, vol. 296, no. 6, pp. E1300–E1310, 2009.
[15] W.Huang, A.Metlakunta, N. Dedousis et al., “Depletion of liver
kupffer cells prevents the development of diet-induced hepatic
steatosis and insulin resistance,”Diabetes, vol. 59, no. 2, pp. 347–
357, 2010.
[16] J. P. Thaler, C.-X. Yi, E. A. Schur et al., “Obesity is associated
with hypothalamic injury in rodents and humans,”The Journal
of Clinical Investigation, vol. 122, no. 1, pp. 153–162, 2012.
[17] Y.-M. Kang, Y. Ma, J.-P. Zheng et al., “Brain nuclear factor-
kappa B activation contributes to neurohumoral excitation in
angiotensin II-induced hypertension,”Cardiovascular Research,
vol. 82, no. 3, pp. 503–512, 2009.
[18] V. C. Calegari, A. S. Torsoni, E. C. Vanzela et al., “Inflammation
of the hypothalamus leads to defective pancreatic islet function,”
The Journal of Biological Chemistry, vol. 286, no. 15, pp. 12870–
12880, 2011.
[19] S. Purkayastha, H. Zhang, G. Zhang, Z. Ahmed, Y. Wang,
and D. Cai, “Neural dysregulation of peripheral insulin action
and blood pressure by brain endoplasmic reticulum stress,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 108, no. 7, pp. 2939–2944, 2011.
[20] M. E. Trujillo and P. E. Scherer, “Adipose tissue-derived factors:
impact on health and disease,” Endocrine Reviews, vol. 27, no. 7,
pp. 762–778, 2006.
[21] E. Maury, K. Ehala-Aleksejev, Y. Guiot, R. Detry, A. Vanden-
hooft, and S. M. Brichard, “Adipokines oversecreted by omental
adipose tissue in human obesity,” The American Journal of
Physiology: Endocrinology and Metabolism, vol. 293, no. 3, pp.
E656–E665, 2007.
8 Journal of Immunology Research
[22] V. Bourlier, A. Zakaroff-Girard, A. Miranville et al.,
“Remodeling phenotype of human subcutaneous adipose
tissue macrophages,” Circulation, vol. 117, no. 6, pp. 806–815,
2008.
[23] I. M. Faust, P. R. Johnson, J. S. Stern, and J. Hirsch, “Diet-
induced adipocyte number increase in adult rats: a new model
of obesity,” The American Journal of Physiology, vol. 235, no. 3,
pp. E279–E286, 1978.
[24] C. Henegar, J. Tordjman, V. Achard et al., “Adipose tissue
transcriptomic signature highlights the pathological relevance
of extracellular matrix in human obesity,” Genome Biology, vol.
9, article R14, 2008.
[25] B. Kabon, A. Nagele, D. Reddy et al., “Obesity decreases
perioperative tissue oxygenation,” Anesthesiology, vol. 100, no.
2, pp. 274–280, 2004.
[26] K. A. Virtanen, P. Lo¨nnroth, R. Parkkola et al., “Glucose uptake
and perfusion in subcutaneous and visceral adipose tissue
during insulin stimulation in nonobese and obese humans,”
Journal of Clinical Endocrinology and Metabolism, vol. 87, no.
8, pp. 3902–3910, 2002.
[27] N. Hosogai, A. Fukuhara, K. Oshima et al., “Adipose tissue
hypoxia in obesity and its impact on adipocytokine dysregula-
tion,” Diabetes, vol. 56, no. 4, pp. 901–911, 2007.
[28] J. Ye, Z. Gao, J. Yin, andQ.He, “Hypoxia is a potential risk factor
for chronic inflammation and adiponectin reduction in adipose
tissue of ob/ob and dietary obese mice,” The American Journal
of Physiology: Endocrinology andMetabolism, vol. 293, no. 4, pp.
E1118–E1128, 2007.
[29] B. Wang, I. S. Wood, and P. Trayhurn, “Dysregulation of the
expression and secretion of inflammation-related adipokines by
hypoxia in human adipocytes,”Pflugers Archiv European Journal
of Physiology, vol. 455, no. 3, pp. 479–492, 2007.
[30] J. Yin, Z. Gao,Q.He,D. Zhou, Z.Guo, and J. Ye, “Role of hypoxia
in obesity-induced disorders of glucose and lipidmetabolism in
adipose tissue,”TheAmerican Journal of Physiology: Endocrinol-
ogy and Metabolism, vol. 296, no. 2, pp. E333–E342, 2009.
[31] Z. Yun, H. L. Maecker, R. S. Johnson, and A. J. Giaccia,
“Inhibition of PPAR𝛾2 gene expression by the HIF-1-regulated
gene DEC1/Stra13: a mechanism for regulation of adipogenesis
by hypoxia,” Developmental Cell, vol. 2, no. 3, pp. 331–341, 2002.
[32] L. Liu, T. P. Cash, R. G. Jones, B. Keith, C. B. Thompson, and
M. C. Simon, “Hypoxia-induced energy stress regulates mRNA
translation and cell growth,” Molecular Cell, vol. 21, no. 4, pp.
521–531, 2006.
[33] K. Zhang and R. J. Kaufman, “From endoplasmic-reticulum
stress to the inflammatory response,”Nature, vol. 454, no. 7203,
pp. 455–462, 2008.
[34] B. P. Tu and J. S. Weissman, “Oxidative protein folding in
eukaryotes: mechanisms and consequences,” Journal of Cell
Biology, vol. 164, no. 3, pp. 341–346, 2004.
[35] C. M. Haynes, E. A. Titus, and A. A. Cooper, “Degradation of
misfolded proteins prevents ER-derived oxidative stress and cell
death,”Molecular Cell, vol. 15, no. 5, pp. 767–776, 2004.
[36] A. Schaeffler, P. Gross, R. Buettner et al., “Fatty acid-induced
induction of Toll-like receptor-4/nuclear factor-𝜅B pathway in
adipocytes links nutritional signalling with innate immunity,”
Immunology, vol. 126, no. 2, pp. 233–245, 2009.
[37] A. Kopp, C. Buechler,M.Neumeier et al., “Innate immunity and
adipocyte function: ligand-specific activation of multiple toll-
like receptors modulates cytokine, adipokine, and chemokine
secretion in adipocytes,” Obesity, vol. 17, no. 4, pp. 648–656,
2009.
[38] O. I. Vitseva, K. Tanriverdi, T. T. Tchkonia et al., “Inducible
toll-like receptor and NF-𝜅B regulatory pathway expression in
human adipose tissue,”Obesity, vol. 16, no. 5, pp. 932–937, 2008.
[39] S. J. Creely, P. G. McTernan, C. M. Kusminski et al.,
“Lipopolysaccharide activates an innate immune system
response in human adipose tissue in obesity and type 2
diabetes,” The American Journal of Physiology: Endocrinology
and Metabolism, vol. 292, no. 3, pp. E740–E747, 2007.
[40] A. Scha¨ffler, J. Scho¨lmerich, and B. Salzberger, “Adipose tissue
as an immunological organ: toll-like receptors, C1q/TNFs and
CTRPs,”Trends in Immunology, vol. 28, no. 9, pp. 393–399, 2007.
[41] J. E. Davis, N. K. Gabler, J. Walker-Daniels, and M. E. Spurlock,
“Tlr-4 deficiency selectively protects against obesity induced by
diets high in saturated fat,”Obesity, vol. 16, no. 6, pp. 1248–1255,
2008.
[42] T. Suganami, T. Mieda, M. Itoh, Y. Shimoda, Y. Kamei, and Y.
Ogawa, “Attenuation of obesity-induced adipose tissue inflam-
mation in C3H/HeJ mice carrying a toll-like receptor 4 muta-
tion,” Biochemical and Biophysical Research Communications,
vol. 354, no. 1, pp. 45–49, 2007.
[43] X. Prieur, T. Roszer, and M. Ricote, “Lipotoxicity in
macrophages: evidence from diseases associated with the
metabolic syndrome,” Biochimica et Biophysica Acta: Molecular
and Cell Biology of Lipids, vol. 1801, no. 3, pp. 327–337, 2010.
[44] P. D. Cani, J. Amar,M. A. Iglesias et al., “Metabolic endotoxemia
initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7,
pp. 1761–1772, 2007.
[45] S. V. Monte, J. A. Caruana, H. Ghanim et al., “Reduction in
endotoxemia, oxidative and inflammatory stress, and insulin
resistance after Roux-en-Y gastric bypass surgery in patients
with morbid obesity and type 2 diabetes mellitus,” Surgery, vol.
151, no. 4, pp. 587–593, 2012.
[46] S. Ghoshal, J. Witta, J. Zhong, W. de Villiers, and E. Eckhardt,
“Chylomicrons promote intestinal absorption of lipopolysac-
charides,” Journal of Lipid Research, vol. 50, no. 1, pp. 90–97,
2009.
[47] P. D. Cani, R. Bibiloni, C. Knauf et al., “Changes in gut micro-
biota control metabolic endotoxemia-induced inflammation in
high-fat diet-induced obesity and diabetes in mice,” Diabetes,
vol. 57, no. 6, pp. 1470–1481, 2008.
[48] G. G.Muccioli, D. Naslain, F. Ba¨ckhed et al., “The endocannabi-
noid system links gut microbiota to adipogenesis,” Molecular
Systems Biology, vol. 6, article 392, 2010.
[49] P. D. Cani, S. Possemiers, T. Van De Wiele et al., “Changes in
gut microbiota control inflammation in obese mice through
a mechanism involving GLP-2-driven improvement of gut
permeability,” Gut, vol. 58, no. 8, pp. 1091–1103, 2009.
[50] A. Scha¨ffler and J. Scho¨lmerich, “Innate immunity and adipose
tissue biology,”Trends in Immunology, vol. 31, no. 6, pp. 228–235,
2010.
[51] B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed
pairing, often flanked by adenosines, indicates that thousands
of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp.
15–20, 2005.
[52] D. O’Carroll, I. Mecklenbrauker, P. P. Das et al., “A Slicer-
independent role for Argonaute 2 in hematopoiesis and the
microRNA pathway,”Genes and Development, vol. 21, no. 16, pp.
1999–2004, 2007.
[53] C. Xiao, L. Srinivasan, D. P. Calado et al., “Lymphoproliferative
disease and autoimmunity in mice with increased miR-17-92
expression in lymphocytes,” Nature Immunology, vol. 9, no. 4,
pp. 405–414, 2008.
Journal of Immunology Research 9
[54] B. Zhou, S. Wang, C. Mayr, D. P. Bartel, and H. F. Lodish, “miR-
150, amicroRNA expressed inmature B and T cells, blocks early
B cell development when expressed prematurely,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 104, no. 17, pp. 7080–7085, 2007.
[55] B. S. Cobb, T. B. Nesterova, E. Thompson et al., “T cell lineage
choice and differentiation in the absence of the RNase III
enzyme Dicer,” Journal of Experimental Medicine, vol. 201, no.
9, pp. 1367–1373, 2005.
[56] C.-Z. Chen, L. Li, H. F. Lodish, and D. P. Bartel, “MicroRNAs
modulate hematopoietic lineage differentiation,” Science, vol.
303, no. 5654, pp. 83–86, 2004.
[57] Q.-J. Li, J. Chau, P. J. R. Ebert et al., “miR-181a is an intrinsic
modulator of T cell sensitivity and selection,” Cell, vol. 129, no.
1, pp. 147–161, 2007.
[58] M. M. W. Chong, J. P. Rasmussen, A. Y. Rudensky, and D.
R. Littman, “The RNAseIII enzyme Drosha is critical in T
cells for preventing lethal inflammatory disease,” Journal of
Experimental Medicine, vol. 205, no. 9, pp. 2005–2017, 2008.
[59] L. A. O’Neill, F. J. Sheedy, and C. E. McCoy, “MicroRNAs:
the fine-tuners of toll-like receptor signalling,” Nature Reviews
Immunology, vol. 11, no. 3, pp. 163–175, 2011.
[60] A. J. Asirvatham, C. J. Gregorie, Z. Hu, W. J. Magner, and
T. B. Tomasi, “MicroRNA targets in immune genes and the
Dicer/Argonaute and ARE machinery components,”Molecular
Immunology, vol. 45, no. 7, pp. 1995–2006, 2008.
[61] T. Bakheet, M. Frevel, B. R. G. Williams, W. Greer, and K. S.
A. Khabar, “ARED: humanAU-rich element-containingmRNA
database reveals an unexpectedly diverse functional repertoire
of encoded proteins,” Nucleic Acids Research, vol. 29, no. 1, pp.
246–254, 2001.
[62] A. J. Asirvatham, W. J. Magner, and T. B. Tomasi, “miRNA
regulation of cytokine genes,” Cytokine, vol. 45, no. 2, pp. 58–
69, 2009.
[63] D. V. Chartoumpekis, A. Zaravinos, P. G. Ziros et al., “Differen-
tial expression of microRNAs in adipose tissue after long-term
high-fat diet-induced obesity in mice,” PLoS ONE, vol. 7, no. 4,
Article ID e34872, 2012.
[64] F. J. Ortega, J. M. Moreno-Navarrete, G. Pardo et al., “MiRNA
expression profile of human subcutaneous adipose and during
adipocyte differentiation,” PLoS ONE, vol. 5, no. 2, Article ID
e9022, 2010.
[65] N. Klo¨ting, S. Berthold, P. Kovacs et al., “MicroRNA expression
in human omental and subcutaneous adipose tissue,” PLoS
ONE, vol. 4, no. 3, Article ID e4699, 2009.
[66] H. M. Heneghan, N. Miller, O. J. McAnena, T. O’Brien, and M.
J. Kerin, “Differential miRNA expression in omental adipose
tissue and in the circulation of obese patients identifies novel
metabolic biomarkers,” Journal of Clinical Endocrinology and
Metabolism, vol. 96, no. 5, pp. E846–E850, 2011.
[67] E. Arner, N. Mejhert, A. Kulyte et al., “Adipose tissue microR-
NAs as regulators of CCL2 production in human obesity,”
Diabetes, vol. 61, pp. 1986–1993, 2012.
[68] H. Xie, B. Lim, and H. F. Lodish, “MicroRNAs induced during
adipogenesis that accelerate fat cell development are downreg-
ulated in obesity,” Diabetes, vol. 58, no. 5, pp. 1050–1057, 2009.
[69] P. Parra, F. Serra, and A. Palou, “Expression of adipose MicroR-
NAs is sensitive to dietary conjugated linoleic acid treatment in
mice,” PLoS ONE, vol. 5, no. 9, Article ID e13005, 2010.
[70] J. C. Strum, J. H. Johnson, J. Ward et al., “MicroRNA 132 regu-
lates nutritional stress-induced chemokine production through
repression of SirT1,”Molecular Endocrinology, vol. 23, no. 11, pp.
1876–1884, 2009.
[71] G. Zhuang, C. Meng, X. Guo et al., “A novel regulator of
macrophage activation: miR-223 in obesity associated adipose
tissue inflammation,” Circulation, vol. 125, no. 23, pp. 2892–
2903, 2012.
[72] Q. Ge, J. Gerard, L. Noel, I. Scroyen, and S. M. Brichard,
“MicroRNAs regulated by adiponectin as novel targets for
controlling adipose tissue inflammation,” Endocrinology, vol.
153, no. 11, pp. 5285–5296, 2012.
[73] A. Chatzigeorgiou, K. P. Karalis, S. R. Bornstein, and T.
Chavakis, “Lymphocytes in obesity-related adipose tissue
inflammation,”Diabetologia, vol. 55, no. 10, pp. 2583–2592, 2012.
[74] M. Poggi, J. Jager,O. Paulmyer-Lacroix et al., “The inflammatory
receptor CD40 is expressed on human adipocytes: contribution
to crosstalk between lymphocytes and adipocytes,” Diabetolo-
gia, vol. 52, no. 6, pp. 1152–1163, 2009.
[75] R. Ogawa, C. Tanaka, M. Sato et al., “Adipocyte-derived
microvesicles contain RNA that is transported into
macrophages and might be secreted into blood circulation,”
Biochemical and Biophysical Research Communications, vol.
398, no. 4, pp. 723–729, 2010.
[76] G. Mu¨ller, M. Schneider, G. Biemer-Daub, and S. Wied,
“Microvesicles released from rat adipocytes and harboring
glycosylphosphatidylinositol-anchored proteins transfer RNA
stimulating lipid synthesis,” Cellular Signalling, vol. 23, no. 7, pp.
1207–1223, 2011.
[77] X. Chen, Y. Ba, L. Ma et al., “Characterization of microRNAs in
serum: a novel class of biomarkers for diagnosis of cancer and
other diseases,”Cell Research, vol. 18, no. 10, pp. 997–1006, 2008.
[78] Y. D’Alessandra, P. Devanna, F. Limana et al., “Circulating
microRNAs are new and sensitive biomarkers of myocardial
infarction,” European Heart Journal, vol. 31, no. 22, pp. 2765–
2773, 2010.
[79] Y. Cheng, N. Tan, J. Yang et al., “A translational study of cir-
culating cell-free microRNA-1 in acute myocardial infarction,”
Clinical Science, vol. 119, no. 2, pp. 87–95, 2010.
[80] M. F. Corsten, R. Dennert, S. Jochems et al., “Circulat-
ing MicroRNA-208b and MicroRNA-499 reflect myocardial
damage in cardiovascular disease,” Circulation: Cardiovascular
Genetics, vol. 3, no. 6, pp. 499–506, 2010.
[81] X. Ji, R. Takahashi, Y. Hiura, G. Hirokawa, Y. Fukushima, and
N. Iwai, “Plasma miR-208 as a biomarker of myocardial injury,”
Clinical Chemistry, vol. 55, no. 11, pp. 1944–1949, 2009.
[82] A. Zampetaki, S. Kiechl, I. Drozdov et al., “Plasma MicroRNA
profiling reveals loss of endothelial MiR-126 and other MicroR-
NAs in type 2 diabetes,” Circulation Research, vol. 107, no. 6, pp.
810–817, 2010.
[83] A. M. McDermott, H. M. Heneghan, N. Miller, and M. J. Kerin,
“The therapeutic potential of microRNAs: disease modulators
and drug targets,” Pharmaceutical Research, vol. 28, no. 12, pp.
3016–3029, 2011.
[84] J.Weiler, J. Hunziker, and J.Hall, “Anti-miRNAoligonucleotides
(AMOs): ammunition to target miRNAs implicated in human
disease?” Gene Therapy, vol. 13, no. 6, pp. 496–502, 2006.
[85] A. Colin, M. Faideau, N. Dufour et al., “Engineered lentiviral
vector targeting astrocytes in vivo,” Glia, vol. 57, no. 6, pp. 667–
679, 2009.
[86] B. D. Brown, M. A. Venneri, A. Zingale, L. S. Sergi, and L. Nal-
dini, “Endogenous microRNA regulation suppresses transgene
expression in hematopoietic lineages and enables stable gene
transfer,” Nature Medicine, vol. 12, no. 5, pp. 585–591, 2006.
10 Journal of Immunology Research
[87] L. E. Bernstein, J. Berry, S. Kim, B. Canavan, and S. K.
Grinspoon, “Effects of etanercept in patients with themetabolic
syndrome,” Archives of Internal Medicine, vol. 166, no. 8, pp.
902–908, 2006.
[88] H. Dominguez, H. Storgaard, C. Rask-Madsen et al., “Metabolic
and vascular effects of tumor necrosis factor-𝛼 blockade with
etanercept in obese patients with type 2 diabetes,” Journal of
Vascular Research, vol. 42, no. 6, pp. 517–525, 2005.
[89] J. Kru¨tzfeldt, N. Rajewsky, R. Braich et al., “Silencing of
microRNAs in vivowith ’antagomirs’,”Nature, vol. 438, no. 7068,
pp. 685–689, 2005.
[90] J. Elme´n, M. Lindow, S. Schu¨tz et al., “LNA-mediated
microRNA silencing in non-human primates,” Nature, vol. 452,
no. 7189, pp. 896–899, 2008.
[91] D. Grimm, K. L. Streetz, C. L. Jopling et al., “Fatality in mice
due to oversaturation of cellular microRNA/short hairpin RNA
pathways,” Nature, vol. 441, no. 7092, pp. 537–541, 2006.
[92] C. R. Sibley, Y. Seow, and M. J. Wood, “Novel RNA-based
strategies for therapeutic gene silencing,” Molecular Therapy,
vol. 18, no. 3, pp. 466–476, 2010.
